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Abstract
Breast cancer (BC) patients have an increased risk of developing cancer therapy-related
cardiac dysfunction (CTRCD) and cardiovascular morbidity, which seems to have a sub-
stantial prognostic impact. Oncologists, in collaboration with dedicated cardiologists, have
the opportunity to perform cardiovascular risk stratification. Despite guideline recommenda-
tions, strategies to detect cardiac damage at an early stage are not structurally implemented
in clinical practice. The perspectives of oncology professionals regarding cardiac surveil-
lance in BC patients have not been qualitatively evaluated. We aim to explore the percep-
tions of oncology professionals regarding cardiac surveillance in BC patients and, more
specifically, the influencing factors of delivering cardiac surveillance. A qualitative study with
semi-structured interviews was conducted and thematically analyzed. Twelve oncology pro-
fessionals participated in this study. Four themes were selected to answer the study objec-
tives: (1) sense of urgency, (2) multidisciplinary collaboration, (3) patient burden, and (4)
practical tools for cardiac surveillance. Most professionals did not feel the need to deliver
cardiac surveillance as they considered the incidence of CTRCD as rare. Multidisciplinary
collaboration was also perceived as unnecessary, and cardiac surveillance was considered
disproportionately burdensome with respect to its benefits. Nevertheless, professionals
affirmed the need for practical tools to deliver cardiac surveillance. Most professionals are
currently unaware of CTRCD incidence and cardiac surveillance benefits. Encouraging mul-
tidisciplinary collaboration and improving their knowledge of cardiotoxic effects of treat-
ments and possibility of early detection can lead to structured cardiac surveillance for breast
cancer patients.
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Introduction
Cancer therapy-related cardiac dysfunction (CTRCD) has an incidence of approximately
30% in patients receiving anthracycline-based chemotherapy and trastuzumab, especially
after prior radiation therapy [1, 2]. Development of cardiovascular morbidity significantly
affects the prognosis of breast cancer (BC) patients (e.g., 5-year heart failure mortality is
>50%; [3–6]). There is increasing evidence for the benefits of detecting CTRCD and treat-
ing patients with early signs of myocardial damage even before the left ventricular ejection
fraction (LVEF) is reduced [7, 8]. Increased interest in cardiac surveillance in cancer
patients resulted in the European Society for Medical Oncology’s (ESMO) formulation of
guidelines and the European Society of Cardiology’s (ESC) position paper that presented
recommendations for current practice [3, 9, 10]. For patients with a high risk of developing
cardiovascular toxicity (e.g., those receiving anthracyclines or trastuzumab), baseline and
3-month monitoring are recommended with cardiac imaging modalities, such as echocardi-
ography or cardiovascular magnetic resonance (CMR), in combination with assessment of
cardiac biomarkers [3, 9, 10].
These recommendations have been adopted in the Dutch national guidelines [11]. Recent
studies have shown that these recommendations are not yet implemented in clinical practice
[12], and several explanations for this discrepancy have been discussed. Physician factors–and
not necessarily patient factors or factors related to the proposed anti-cancer therapy–seem cru-
cial in clinical decision making regarding cardiac surveillance in cancer patients [13]. Knowl-
edge of potential barriers for cardiac surveillance could provide insights and objectives for
improvement. Therefore, in this study, we aim to qualitatively explore the perceptions of
oncology professionals regarding cardiac surveillance in BC patients and, more specifically,
the influencing factors of delivering cardiac surveillance.
Methods
Design
We conducted a qualitative study with semi-structured interviews to explore oncology profes-
sionals’ views and expectations regarding cardiac surveillance in BC patients with a high car-
diovascular risk. The consolidated criteria for reporting qualitative studies (COREQ) checklist
was used to ensure complete reporting of methodology. A waiver was provided by the Medical
Research Ethics Committee of Arnhem-Nijmegen because the study did not need an ethical
review. The study was conducted in accordance with the principles of ICH Good Clinical Prac-
tice, applicable privacy requirements, and principles of the Declaration of Helsinki.
Participants and recruitment
A purposive sample with maximum variation in gender, work experience, and hospital type
was selected with the aim to reflect the true variation in characteristics observed in clinical
practice. Twelve oncology professionals specialized in BC care participated in this study:
oncologists (N = 6), a cancer epidemiologist (N = 1), and oncology nurse practitioners (N = 5).
In this paper, oncology professionals are referred to as professionals, unless otherwise speci-
fied. The professionals worked at the medical oncology department in either a university or
general hospital. They were selected after consulting the head of the respective oncology
departments. Eligibility was based on their experience in BC care: a minimum of 1 year in
their current function. The coordinating investigator contacted eligible professionals (N = 16)
from seven different hospitals via phone and invited them to participate in this qualitative
study. Twelve professionals (75%) agreed to participate. Four professionals were unwilling to
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participate: one did not have any experience with cardiovascular diseases in BC patients,
whereas the other three declined owing to logistic reasons.
Data collection
A semi-structured interview guide was developed, theoretically based on the seven domains of
the Tailored Implementation for Chronic Diseases (TICD) checklist (Table 1), which is a syn-
thesis of 12 existing checklists for identifying determinants of practice and factors that prevent
or enable improvements in healthcare professional practice [14].
The interview guide was repeatedly reviewed by all investigators to ensure the feasibility
and completeness of the topics; it consisted of open questions regarding clinical protocols,
awareness, multi-disciplinary collaboration, organizational structure, and resources (S1 File).
All interviews started with the same opening question about clinical protocols for cardiac sur-
veillance in BC patients. All seven TICD domains were discussed. During the interviews, sum-
maries, probes and prompts were used to ensure correct interpretation of professionals’
perceptions and encourage outspokenness [15].
Individual face-to-face interviews were conducted in a private room at the hospital where
the participant was employed. Baseline characteristics were collected after informed consent
was obtained and before the interview began. The interviews were conducted by a 35-year-old,
independent, female health sciences student (MSc) with 2 years of work experience in the field
of oncology (author LD). The interviewer was unknown to the professionals, which allowed
Table 1. Interview topics.
TICD checklist domain Determinants
Guideline factors Quality and clarity of recommendations
Accessibility and source of recommendations
Recommended clinical intervention feasibility and accessibility
Compatibility of recommended behavior
Practice with recommendations
Individual health professional factors Knowledge and skills
Attitude and understanding towards recommendations
Professional behavior
Patient factors Patient needs, knowledge and preferences
Professional interactions Communication and influence
Team processes
Referral processes
Incentives and resources Availability of necessary resources
(Non)financial incentives
Information system
Quality assurance systems and assistance for adherence




Social, political and legal factors Individual influence
Contracts
Funding policies
TICD: Tailored implementation for chronic diseases [14].
https://doi.org/10.1371/journal.pone.0249067.t001
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them to express their experiences and perceptions without inhibitions. All interviews were
conducted in Dutch, all quotes were translated to English with the forward backward proce-
dure for translation reliability.
The interview duration ranged from 21 to 64 min (median: 36 min). The interviews were
audio-recorded, transcribed verbatim, and checked for transcription errors. Field notes were
made immediately after the interviews to record observations, capture initial ideas on the top-
ics, and reflect on the methodology (e.g., interview guide refinement). Interview techniques
were practiced with a simulation interview to enhance the interview skills and obtain feedback
from more experienced researchers.
Data analysis
Thematic analysis as outlined by Braun and Clarke was used, an inductive, semantic and realist
approach was applied. Thematic analysis consists of six steps: familiarizing with the data, gen-
erating initial codes, searching for themes, reviewing themes, defining and naming themes,
and writing (Table 2; [16]). The supplementary 15-point checklist ensured the correct use of
the thematic analysis method.
The first four interviews were coded by three researchers independently of each other and sub-
sequently checked for inconsistencies and similarities; the remaining interviews were coded by two
independent researchers. Inconsistencies were discussed in analysis meetings with the research
team. After the first three interviews, the analysis step “searching for themes” was performed. After
the remaining interviews, each theme was further considered and refined; illustrative quotes were
also selected. Data saturation was defined as the point where additional interviews did not lead to
any codes that introduced a new topic, which was reached after ten interviews. Two more inter-
views confirmed saturation and ensured maximum variation in the sample.
After transcribing the interviews, 740 codes were generated and grouped in 32 clusters,
such as multidisciplinary collaboration, continuity of care, burden, need for knowledge,
urgency, logistics, awareness, personalized care, research, visibility of late cardiac effects, and
Table 2. Six steps of thematic analysis.
Phase Description of the process
1. Familiarizing with the
data
Interviews were transcribed (LD); the transcripts were read and re-read; and initial
ideas for topics were discussed in the research team (LD, YK).
2. Generating initial codes All transcripts were coded by two researchers independently of each other (LD, NvZ,
YK). Noteworthy features of the data were coded in a systematic fashion across the
entire data set, collating data relevant to each code. The codes were presented and
discussed in the research team (LD, YK, HV).
3. Searching for themes Codes were collated into potential themes, gathering all data relevant to each potential
theme. A preliminary description of potential themes and subthemes was made and
discussed (LD, YK, HV).
4. Reviewing themes The preliminary themes were checked for consistency with the original data (LD, YK).
Inconsistencies were discussed, and the themes were further explored (LD, YK). The
main themes and subthemes were revised accordingly and further described (LD, YK)
and reviewed (YK, HV, SEM, DJS, AHEMM, FA).
5. Defining and naming
themes
The specifics of each theme were discussed, and names and definitions of themes were
refined (YK, LD, HV, SEM, DJS, AHEMM, FA).
6. Producing the report A first draft of the results was written (YK) and reviewed (HV, SEM, DJS, AHEMM,
FA).
The quotes were selected to clarify the presented data; the report was further discussed
(LD, YK, SEM, HV) and adjusted (YK). The report was critically assessed by the
research team and further modified to adequately present the themes with verbatim
quotes (YK, LD, HV, SEM, DJS, AHEMM, FA).
https://doi.org/10.1371/journal.pone.0249067.t002
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cost effectiveness. The recurring themes within these clusters were discussed to identify the
final themes to answer the research question.
Regular data collection and analysis meetings were scheduled with the interviewer and
experienced researchers, which resulted in researcher triangulation and peer review in all
phases of the study; this enhanced the methodological quality, reliability, data dependability,
and accuracy [15, 17, 18]. Additionally, an audit trail improved the confirmability of the study
[15]. Data management was supported by ATLAS.ti software (version 8; Scientific Software
Development GmbH, Berlin, Germany).
Results
Between January and May 2019, 12 oncology professionals in BC care from both general and
university hospitals in the Netherlands were interviewed. The mean age of the participants was
52.5 years (range: 36–62 years). Two of the 12 participants were male (17%), and 10 were
female (83%). Six of the professionals were oncologists (50%), five were nurse practitioners
(42%), and one was an epidemiologist (8%). Most professionals had a master’s degree (N = 7;
58%) and had >6 years of work experience in their current function (N = 10; 83%). Eight pro-
fessionals (67%) worked at a general hospital, whereas four (33%) worked at a university hospi-
tal. The participating professionals were employed at seven different hospitals. Maximum
variation was achieved for age and work experience. The baseline characteristics of the study
participants are presented in Table 3.
The following sections describe current practice based on the explanations given by the pro-
fessionals. The four themes that answer the study objectives are also discussed: (1) sense of
urgency, (2) multidisciplinary collaboration, (3) patient burden, and (4) practical tools for car-
diac surveillance (Fig 1).
Current practice
Most oncology professionals (N = 10; 83%) stated that cardiac surveillance for BC patients is
not structurally performed in their hospital. The majority of professionals (N = 10 [83%]; from
5 out of 7 [71%] hospitals) disclosed that cardiac monitoring focused on the performance of a
multigated acquisition (MUGA) scan for the assessment of the LVEF prior to and during
Table 3. Baseline characteristics of participants.
Participant Age � (years) Function Sex Highest level of education Work experience (years) � Work setting ��
1 54 Nurse practitioner Female Master 5 University hospital
2 58 Nurse practitioner Female Master 18 Non-university hospital
3 54 Oncologist Female PhD 16 Non-university hospital
4 59 Nurse practitioner Female Master 7 Non-university hospital
5 51 Nurse practitioner Male Master 11 Non-university hospital
6 39 Oncologist Female PhD 7 University hospital
7 59 Oncologist Female PhD 20 Non-university hospital
8 62 Epidemiologist Female PhD 36 Non-university hospital
9 51 Nurse practitioner Female Master 9 Non-university hospital
10 42 Oncologist Female PhD 7 University hospital
11 41 Oncologist Female Master 8 University hospital
12 36 Oncologist Male Master 3 Non-university hospital
�At time of interview;
�� Non-university hospital: General hospital or top clinical teaching hospital.
https://doi.org/10.1371/journal.pone.0249067.t003
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trastuzumab treatment for HER2+ BC patients. Patients receiving other (high-risk) cardiotoxic
treatments did not receive any form of cardiac surveillance unless it was clinically indicated
owing to the development of cardiac symptoms or patients already received it owing to pre-
existing cardiovascular comorbidities. Only two professionals from two different hospitals men-
tioned the recent implementation of a cardio-oncology referral department for cancer patients
receiving high-risk cardiotoxic treatment. At these dedicated cardio-oncology outpatient clinics,
cardiovascular risk stratification and cardiotoxicity monitoring during cancer treatment are
performed. Notably, all professionals indicated that strict clinical protocols (based on guide-
lines) for the detection of cardiotoxicity during and after cancer treatment are lacking.
Sense of urgency
All professionals were aware of the cardiotoxic effects of anthracycline- and trastuzumab-
based regimens. They all clarified that their delivery of cardiac surveillance was mainly driven
by their sense of (or lack of) urgency; they did not perform any form of cardiac surveillance
mostly because they did not recognize the advantages.
The assumed low incidence of cardiac events in their patient population was the main cause
and played a key role in the professionals’ clinical decision making. Oncologists indicated that
they rarely treated BC patients with CTRCD; therefore, they perceived the occurrence of
(adverse) cardiac events during cancer treatment as rare. Additionally, a reduction in LVEF was
considered as reversible and therefore not important to detect using cardiac imaging.
“I can’t remember anyone from recent years who I referred to a cardiologist, no one who
expressed complaints that could be of a cardiac nature and then came back with heart failure.
And that could mean two things: either those patients weren’t there, or we haven’t searched
properly.” (P6)
Most professionals did not feel the need to change current practice regarding cardiac sur-
veillance despite the increasing awareness on cardiotoxicity among specialists.
“I remember a patient–she really had heart failure. The question is, if we had done things dif-
ferently and screened the patient before cancer treatment, we probably couldn’t have pre-
vented it anyway. So, in that case, I believe we’re still doing everything as we should, and we
don’t have to change anything, but yes, that one patient–if I may say–was very unlucky. It did
have a large impact; yes.” (P12)
Fig 1. Thematic overview.
https://doi.org/10.1371/journal.pone.0249067.g001
PLOS ONE Oncology professionals’ perspectives towards cardiac surveillance in breast cancer patients
PLOS ONE | https://doi.org/10.1371/journal.pone.0249067 March 31, 2021 6 / 13
Most professionals were not convinced that increased cardiac monitoring can prevent
CTRCD or improve quality of life. Those in favor of cardiac monitoring mentioned their col-
leagues’ lack of knowledge on the topic as a barrier. Similarly, the perception of oncologists
that cardiology waiting lists are usually long prevented them from referring their patients for
cardiac screening because they feared this would significantly delay cancer treatment. Some
oncologists disclosed that cardiac monitoring in cancer patients was not a priority for cardiol-
ogists because of anticipated poor cancer prognosis.
“When we say, ‘cancer patient’, the patient’s prognosis is not always correctly interpreted by
cardiologists. It quickly sounds like, ‘It’s cancer. We don’t have to proceed with monitoring
quickly because the prognosis is already limited.’ But that’s exactly the question. Obviously,
this is true sometimes, but there are also situations in which we expect patients to have many
more years to go; I feel [that] it sometimes influences a cardiologist’s advice too much.” (P10)
All professionals agreed that increased knowledge of CTRCD, improved awareness of all
involved disciplines and practitioners, and more proactive and preventive behavior are impor-
tant. Knowledge, experience, or patient stories may result in an increased sense of urgency of
professionals regarding cardiac surveillance.
“And then, I had a patient with severe cardiac damage, and she told me, ‘It was completely
not recognized at all, my cardiac complaints.’ She was in tears. Now, I recognize how impor-
tant it is to properly inquire about potential [cardiac] complaints.” (P4)
Multidisciplinary collaboration
Multidisciplinary collaboration between oncologists and dedicated cardiologists highly influ-
enced the manner in which cardiac surveillance was organized. Two oncologists involved in
multidisciplinary cardio-oncology collaboration acknowledged that this facilitated communi-
cation and resulted in more structured cardiac surveillance in BC patients.
“For us, the logistics are now very easy; we have one contact person, someone who evaluates
the risks of a patient [. . .]. Sometimes we felt MUGA results were not sensitive enough. Now
[with echo], we know more and are able to make well-thought-out decisions [. . .]. Follow-up
is every three months unless it is indicated to schedule it earlier.” (P11)
Multidisciplinary collaborations were often initiated after combined research projects and
were implemented by dedicated professionals, both in oncology and cardiology, who have
intrinsic motivation and a mutual interest in improving (cardiovascular) clinical outcomes of
cancer patients.
“I see that most things are only achieved when a few people start collaborating. That is the
way it works. It often starts with research collaborations.” (P8)
All professionals perceived multidisciplinary cardio-oncology collaboration as an impor-
tant asset in delivering holistic care that takes into account patients’ mental, physical, and
social well-being.
“I am always very medically involved, and the nurse, in my opinion, sees the patients and their
[social] system. And I think that the nurse can offer a whole package, more than I can.” (P11)
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Professionals without an established cardio-oncology department (N = 10; 83%) revealed
that they refer their BC patients to a cardiologist only when the patients have a history of car-
diac events. Many of these professionals perceived occasional consultation with a cardiologist
as sufficient, given that they considered CTRCD as a rare complication. As such, they believed
that multidisciplinary collaboration is not necessary nor recommended in the literature.
“There is no standard collaboration; [it occurs] only in acute situations. It’s just not a frequent
complication. But then again, with that last patient [with cardiac damage], well, sometimes
not all specialists completely understand or know what kind of treatment we use. I think it’s
too easy to assume that cardiac damage during treatment is related to that treatment. It’s
sometimes not clear [. . .]. There is not enough evidence to initiate something or to structurally
collaborate. At least we haven’t done that so far, and it’s also not in the guidelines.” (P7)
Patient burden
Professionals considered the occurrence of CTRCD as rare and therefore choose to limit
informing patients regarding cardiotoxicity risk in an effort to “unburden” them. They stated
that they want to avoid overwhelming their patients with extensive information on possible
cardiac side effects before the start of essential or even life-saving cancer treatment. Moreover,
they felt conflicted in disclosing complications they perceived as rare. Professionals also
believed that patients are not very concerned about their cardiovascular health when first diag-
nosed with BC and also not during or after cancer treatment because staying alive is assumed
to be considered of higher importance after a cancer diagnosis.
“It was just never a reason to give a different treatment. You just explain it. Patients are not
very concerned with it [potential cardiac damage]. They are more like, ‘Do I need to go to a
cardiologist? Ok then’ but never concerned about their cardiac function. But, of course, we
don’t know what they’re thinking when they’re at home.” (P11)
Nonetheless, all professionals emphasized that quality of life after cancer treatment is an
important topic to discuss with patients. They explained that long-term effects should be con-
sidered more often during patient counselling.
“Actually, I think we all want the same thing, which is keeping patients alive. But especially
with a good quality of life. We don’t do that if we cure patients of cancer but then they die
because of heart failure. If that’s the case, we did something drastically wrong or, at least, not
as we’d wish. In that case, we should learn from this and do something about it.” (P6)
Continuity of care, both during BC treatment and during follow-up, was considered essen-
tial to unburden patients. Patients being assessed by different cardiologists during consecutive
consultations was perceived by professionals as a negative aspect of cardiac care. Most profes-
sionals did not feel the need for patients to regularly visit different healthcare specialists
involved in the care process (e.g., surgeon, radiotherapist, and cardiologist). Specifically, nurse
practitioners underlined the importance of a familiar face for patients, and they recommended
healthcare coordination via one professional to improve healthcare quality and accelerate deci-
sion making.
“Patients were seen by so many specialists, and then they returned to me. And I was like,
‘What was the additional value of all these separate visits?’ [. . .] It’s good to get to know
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patients, coordinate their trajectory, monitor [them] more easily, and notice when something
is going wrong [. . .]. It’s good for the continuity we offer if I’m the main contact, then you’re
more like ‘When was the last echocardiography? We need to request a new evaluation.’” (P5)
Nurse practitioners stated that continuity of care for BC patients has added value and per-
ceived their involvement in the care process, from start to finish, as a strength. Continuity sup-
ports nurse practitioners in delivering personalized care. Health changes can be more easily
detected, and health education can be tailored to patients’ needs.
“That is the advantage of knowing people, that you don’t just check things off your list. But
you’re more like, ‘Who do I have in front of me and to what extent does each aspect [of com-
plaints and health] need attention?’” (P5)
Practical tools for cardiac surveillance
All professionals acknowledged the need for practical tools in delivering cardiac surveillance
for BC patients. They also underlined the need for clinical protocols and guidelines for cardiac
surveillance, with a focus on risk stratification, to distinguish between high- and low-cardio-
vascular-risk patients and tailor cardiac surveillance accordingly. Oncologists stated that it is
difficult to recognize CTRCD without proper knowledge.
“It would be great if we knew, for breast cancer, if we could identify when someone has a
reduction in LVEF during treatment or shows certain specific cardiac complaints or has a risk
profile. That you would know that this is a high-risk patient I need to follow up for the next
four to five years.” (P11)
Most professionals expressed the need for evidence-based guidelines for cardiac surveil-
lance and their structured implementation in current clinical practice.
“I really think you need to make a guideline for this [cardiac surveillance]. Not everyone
should just start doing things. We need to prevent an abundance of initiatives without proper
support from a guideline.” (P8)
Oncologists disclosed a knowledge gap regarding the necessity for cardiac surveillance,
which is mainly due to a lack of data on long-term benefits and cost effectiveness.
“There is always a number-needed-to-harm and a consideration on how many patients are
burdened by failed medical activities versus the benefits. That is an important question.” (P3)
All professionals shared the opinion that changes in healthcare practice should be evidence
based and require an initiative from professionals themselves.
Discussion
In this qualitative study, we explored oncology professionals’ perspectives regarding cardiac sur-
veillance in BC patients. Most professionals included in our study did not feel the need to
deliver cardiac surveillance as they perceived the incidence of CTRCD in BC patients as low. In
addition, most professionals believed that a decline in LVEF during cancer treatment is either
spontaneously reversible without pharmacological interference or persistent and refractory to
heart failure therapy. Burdening patients with information on the potential cardiotoxic effects
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of cancer treatment, performing cardiovascular risk stratification, or initiating cardiac monitor-
ing were therefore perceived as logistically challenging, unnecessary, and even disproportionate
with respect to potential benefits. Nevertheless, there was increased awareness on cardiotoxicity
risks and potential advantages of cardiac monitoring for certain cancer patients. The oncology
professionals highlighted a knowledge gap concerning this topic and emphasized the need for
strict guidelines to ensure the delivery of tailored cardiac surveillance in BC care.
Contrary to the perception of oncology professionals in our study, cardiotoxicity is a com-
mon side effect of BC treatments, with up to 30% of patients developing heart failure after
high-risk cardiotoxic treatments (e.g., anthracyclines and trastuzumab; [1–3]). Cardiovascular
disease mortality risk even exceeds cancer mortality risk in this population [19–21]. Chemo-
therapy-induced cardiomyopathy was traditionally considered to have a poor prognosis and
was often refractory to heart failure treatment. Recent studies, however, have suggested that a
reduction in LVEF can be mitigated when cardiotoxicity is detected at an early stage and
timely intervention is provided [7, 8]. Notably, almost all anthracycline-induced cardiotoxicity
(98%) can be detected in the first year after treatment [22].
Measurement of global longitudinal strain using echocardiography is a reproducible tech-
nique to detect early signs of cardiac dysfunction [23, 24]. Additionally, myocardial edema and
diffuse fibrosis present even in early stages of CTRCD can be detected with CMR mapping
sequences [25, 26]. Although recent guidelines (national and international) indicate serial
monitoring with cardiac imaging in patients receiving high-risk cardiotoxic cancer treatments
[9–11], these guidelines are not implemented in clinical care, and healthcare professionals
seem to be unaware of their necessity [12].
This finding regarding low awareness among professionals is consistent with results of a
qualitative study on BC patients conducted by our research group: Patients stated that their
treating professionals were unaware of cardiac side effects of cancer regimens and that their
cardiac events were often not timely recognized [27]. Physician factors, and not necessarily
patient factors or factors related to cardiotoxicity of anti-cancer therapy, are crucial in clinical
decision making regarding cardiac surveillance in cancer patients [13]; therefore, increasing
awareness among healthcare professionals is important. Oncology professionals perceive car-
diac monitoring as indicated when their patients have already developed symptoms and signs
of cardiac dysfunction [28]. At this stage, cardiac damage may be irreversible even though this
could have been prevented with surveillance regimens at an earlier stage [7, 8].
Evidence-based specific guidelines are needed to ensure effective clinical protocols and
establish partnerships between nurse practitioners and physicians in the oncology, cardiology,
and radiology departments. This collaboration can promote knowledge and shared responsi-
bility among professionals regarding cancer therapeutics, cardiotoxic effects, early cardiac
damage detection strategies, and cardioprotective treatments [29–31]. Moreover, guidelines
should state the survival and quality-of-life benefits of surveillance as well as cost effectiveness
to enhance professionals’ sense of urgency. A multidisciplinary collaboration can also improve
the prognosis and quality of life of BC patients. For survivors of childhood malignancies, struc-
tured cardiac surveillance, often organized in dedicated multidisciplinary outpatient clinics,
improve outcomes on morbidity and frequency of inpatient admissions [32].
In conclusion, cardiac surveillance and early detection of CTRCD can improve prognosis
in BC patients [33]. Professionals seem to underestimate the need for cardiac surveillance; they
stress the need for and importance of clinical tools and clear guidelines. Awareness on the
importance of cardiac surveillance for cancer patients should be increased, and dedicated mul-
tidisciplinary cardio-oncology outpatient clinics can help realize this goal. As cardio-oncology
is a relatively young clinical field, future research has to close the knowledge gaps concerning
the long-term benefits of cardiac surveillance and optimal surveillance strategies.
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Implications for practice
• Knowledge of cardiotoxic effects and possibility of early detection is essential to reduce long-
term cardiac damage.
• Oncology professionals express a need for structured clinical protocols to provide cardiac
surveillance based on recommendations for all high-risk BC patients.
• Multidisciplinary collaboration between the cardiology and oncology departments is impor-
tant to structure and coordinate cardiac surveillance for BC patients, and collaborative
research projects can catalyze this process.
Supporting information
S1 Table. Interview guide healthcare professionals. A table is presented with the interview
guide; all main questions as well as potential follow-up questions are listed. The order of the
questions is based on the seven domains of the TICD checklist, which was the theoretical basis
of the interview guide.
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